Clinical Trials Logo

Filter by:
NCT ID: NCT00093093 Completed - Chronic Hepatitis C Clinical Trials

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

VISER2
Start date: June 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.

NCT ID: NCT00091949 Completed - Stroke Clinical Trials

Insulin Resistance Intervention After Stroke Trial

IRIS
Start date: February 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.

NCT ID: NCT00091715 Completed - Clinical trials for Pulmonary Hypertension

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.

NCT ID: NCT00091637 Completed - Clinical trials for Acute Myocardial Infarction

Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)

Start date: April 2004
Phase: Phase 3
Study type: Interventional

In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days.

NCT ID: NCT00091598 Completed - Clinical trials for Pulmonary Hypertension

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

Start date: January 2004
Phase: Phase 3
Study type: Interventional

The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.

NCT ID: NCT00091377 Completed - Ovarian Cancer Clinical Trials

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Start date: August 2004
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Phenoxodiol may help cisplatin and paclitaxel kill more tumor cells by making tumor cells more sensitive to the drugs. PURPOSE: This randomized phase I/II trial is studying the side effects of phenoxodiol when given together with either cisplatin or paclitaxel and to see how well they work in treating patients with recurrent late-stage ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that has not responded to treatment with drugs such as paclitaxel, docetaxel, cisplatin, or carboplatin.

NCT ID: NCT00090766 Completed - Clinical trials for Cytomegalovirus Infections

A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This study will assess the safety and pharmacokinetics of Valcyte syrup in pediatric solid organ transplant recipients. The anticipated time on study treatment is 3-12 months and the target sample size is less than 100 individuals.

NCT ID: NCT00090753 Completed - Anemia Clinical Trials

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

Start date: October 2004
Phase: Phase 3
Study type: Interventional

This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia. Eligible patients were those who were receiving stable maintenance therapy with methoxy polyethylene glycol-epoetin beta or erythropoiesis stimulating agents (ESAs) in Phase II or III clinical studies. They continued to receive methoxy polyethylene glycol-epoetin beta or comparator ESAs at the same weekly dose and by the same route of administration (sc or iv) as in the qualifying studies.

NCT ID: NCT00090519 Completed - Clinical trials for Diabetic Retinopathy

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Start date: February 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.

NCT ID: NCT00090363 Completed - Prostate Cancer Clinical Trials

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

Start date: July 2004
Phase: Phase 2
Study type: Interventional

This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill). The study will also provide further information on the safety of ZD4054 (Zibotentan).